Cancer therapies can lead to a broad spectrum of cardiovascular complications. Among these, cardiotoxicities remain of prime
Abstract
Cancer therapies can lead to a broad spectrum of cardiovascular complications. Among these, cardiotoxicities remain of prime concern, but vascular toxicities have emerged as the second most common group. The range of cancer therapies with a vascular toxicity profile and the clinical spectrum of vascular toxic effects are quite broad. Historically, venous thromboembolism has received the greatest attention but, over the past decade, the arterial toxic effects, which can present as acute vasospasm, acute thrombosis and accelerated atherosclerosis, of cancer therapies have gained greater recognition. This Review focuses on these types of cancer therapy-related arterial toxicity, including their mechanisms, and provides an update on venous thromboembolism and pulmonary hypertension associated with cancer therapies. Recommendations for the screening, treatment and prevention of vascular toxic effects of cancer therapies are outlined in the context of available evidence and society guidelines and consensus statements. The shift towards greater awareness of the vascular toxic effects of cancer therapies has further unveiled the urgent needs in this area in terms of defining best clinical practices. Well-designed and well-conducted clinical studies and registries are needed to more precisely define the incidence rates, risk factors, primary and secondary modes of prevention, and best treatment modalities for vascular toxicities related to cancer therapies. These efforts should be complemented by preclinical studies to outline the pathophysiological concepts that can be translated into the clinic and to identify drugs with vascular toxicity potential even before their widespread clinical use.
PMID: 32218531 [PubMed - as supplied by publisher]
31 March 2020
12:10
Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
12:10
In reply to this message
pubmed: ctoall&ca or conall
Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review.
//www.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif Related Articles
Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review.
J Neuroimmunol. 2019 07 15;332:126-134
Authors: Enriquez CAG, Espiritu AI, Pasco PMD
Abstract
The review assessed the efficacy and tolerability of mitoxantrone in patients with neuromyelitis optica spectrum disorder (NMOSD). Eight articles were reviewed with a total of 117 patients. Annualized relapse rate and progression of disability dramatically decreased post-treatment in most studies. Mitoxantrone was generally tolerated. Only one patient developed acute myeloid leukemia, which lead to septicemia and death. No serious cardiotoxicity was reported. Mitoxantrone may be effective in reducing the frequency of relapse and slowing down the progression of disability in patients with NMOSD. The risk of cardiotoxicity and leukemia detains it as a second-line agent for NMOSD.
PMID: 31005713 [PubMed - indexed for MEDLINE]
13:14
Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
13:14
In reply to this message
pubmed: caandvteortroorpul
Anticoagulant Therapy for Venous Thromboembolism in Cancer.
Related Articles
Anticoagulant Therapy for Venous Thromboembolism in Cancer.
N Engl J Med. 2020 Mar 29;:
Authors: Lee AYY
PMID: 32223115 [PubMed - as supplied by publisher]
13:14
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
13:14
In reply to this message
pubmed: caandvteortroorpul
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Related Articles
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
N Engl J Med. 2020 Mar 29;:
Authors: Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, Sueiro MR, Lambert C, Gussoni G, Campanini M, Fontanella A, Vescovo G, Verso M, Caravaggio Investigators
Comments
Post a Comment
اكتب تعليق حول الموضوع